Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
Sponsor: McMaster University
This PHASE2/PHASE3 trial investigates Eosinophilic Bronchitis and Steroid and/or Prednisone Dependent Asthma and is currently completed. McMaster University leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
▶ Show 1 earlier version
-
Jan 2017 — May 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- McMaster University
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .